Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
Cemiplimab-rwlc injection is used to treat a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread (metastatic) or cannot be cured by surgery or radiation (locally advanced).
Cemiplimab-rwlc injection is also used to treat a type of skin cancer called basal cell carcinoma (BCC) that cannot be removed by surgery (locally advanced) or that has spread (metastatic) in patients who have received previous treatment with a hedgehog pathway inhibitor (HHI) or who cannot receive treatment with a HHI.
Cemiplimab-rwlc injection is also used as a first-line treatment for non-small cell lung cancer (NSCLC) that has not spread and cannot be removed by surgery or radiation (locally advanced), or that has spread (metastatic) in patients whose tumors express high PD-L1 and do not have an abnormal EGFR, ALK , or ROS1 gene. Your doctor will perform a test to check for the PD-L1 tumor before you receive this medicine.
Cemiplimab-rwlc is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms: